June 20, 2007 - Moved to new location - Walnut Hill Lane, Irving, Texas. September 6, 2007 - The merger with Biotechnology Holdings Partners, LP, was completed by the registration of the Intellectual Property transfer with the United States Patent and Trademark Office (USPTO). November/December, 2007 - First web site published. February, 2008 - Several Signe links came on-line at Google - search term "Signe BioPharma Inc". March, 2008 - The European Patent Office (EPO) has notified Signe that two patents are near award. The first is the Brachytherapy (local cancer) part of the Breast Cancer Eradication Program application. The second is based on the Genetic Screening application and is a test for breast cancer susceptibility. Additionally, the USPTO has indicated that the pending Anti-Estrogen Combination application has patentable subject matter.
TRANSGENIC PROTEINS - SECRETORY IMMUNE SYSTEM ANTIBODIES
SIGNE SCIENCE NEWS
Three Manuscripts in Preparation - to be submitted as the first publications from Signe BioPharma Inc.
Genomics search methods coupled with molecular cloning will identify new proprietary diagnostic markers for breast cancer.
A new genetics (FISH) based test kit is being developed to identify breast, prostate, bladder and kidney cancers at the early onset stage before other diagnostic methods are useful. These tests use readily accessible body fluids.
